modelChlortetracycline

Diagram of Chlortetracycline

Extends from Pharmacolibrary.Drugs.ATC.D.D06AA02.

Information

name:Chlortetracycline
ATC code:D06AA02
route:oral
compartments:1
dosage:500mg
volume of distribution:0.9L
clearance:40mL/min
other parameters in model implementation

Chlortetracycline is a broad-spectrum tetracycline antibiotic primarily used for topical treatment of skin infections and for veterinary purposes. It was formerly used systemically in humans but is now largely replaced by other tetracyclines. Currently, its main human use is in ophthalmic ointments and for superficial skin infections. Chlortetracycline is not widely used systemically in clinical human medicine today.

Pharmacokinetics

Estimated pharmacokinetic model for adult humans, oral route, as no dedicated human systemic PK studies with reported parameters exist. Values inferred from pharmacokinetic knowledge of tetracyclines, as no direct published PK study for chlortetracycline in humans is identified.

References

  1. Zhang, Y, et al., & Yu, M (2022). Florfenicol/Chlortetracycline Effect on Pharmacodynamic Indices for Mutant Selection of . Microbial drug resistance (Larchmont, N.Y.) 28(7) 832–840. DOI:10.1089/mdr.2022.0008 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35723674

  2. Cazer, CL, et al., & Gröhn, YT (2018). Expanding behavior pattern sensitivity analysis with model selection and survival analysis. BMC veterinary research 14(1) 355–None. DOI:10.1186/s12917-018-1674-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/30453986

  3. Cazer, CL, et al., & Gröhn, YT (2017). Monte Carlo Simulations Suggest Current Chlortetracycline Drug-Residue Based Withdrawal Periods Would Not Control Antimicrobial Resistance Dissemination from Feedlot to Slaughterhouse. Frontiers in microbiology 8 1753–None. DOI:10.3389/fmicb.2017.01753 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29033901

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)